Altimmune Inc

Company Profile

Altimmune Inc had its IPO on 2005-10-06 under the ticker symbol ALT.

The company operates in the Healthcare sector and Biotechnology industry. Altimmune Inc has a staff strength of 52 employees.

Stock update

Shares of Altimmune Inc opened at $4.23 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $4.19 - $4.43, and closed at $4.32.

This is a +3.1% increase from the previous day's closing price.

A total volume of 3,666,821 shares were traded at the close of the day’s session.

In the last one week, shares of Altimmune Inc have slipped by -60.58%.

Altimmune Inc's Key Ratios

Altimmune Inc has a market cap of $544.53 million, indicating a price to book ratio of 2.5847 and a price to sales ratio of 162.9822.

In the last 12-months Altimmune Inc’s revenue was $-68000 with a gross profit of $-70520000 and an EBITDA of $-87612664. The EBITDA ratio measures Altimmune Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Altimmune Inc’s operating margin was 128902.94% while its return on assets stood at -25.73% with a return of equity of -44.07%.

In Q4, Altimmune Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.7%.

Altimmune Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Altimmune Inc’s profitability.

Altimmune Inc stock is trading at a EV to sales ratio of 99.2173 and a EV to EBITDA ratio of -3.7915. Its price to sales ratio in the trailing 12-months stood at 162.9822.

Altimmune Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$206.93 million

Total Liabilities

$17.05 million

Operating Cash Flow

$0

Capital Expenditure

$38000

Dividend Payout Ratio

0%

Altimmune Inc ended 2023 with $206.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $206.93 million while shareholder equity stood at $185.29 million.

Altimmune Inc ended 2023 with $0 in deferred long-term liabilities, $17.05 million in other current liabilities, in common stock, $-377884000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $111.10 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Altimmune Inc’s total current assets stands at $192.81 million while long-term investments were $0 and short-term investments were $73.78 million. Its net receivables were $173000.00 compared to accounts payable of $4.80 million and inventory worth $0.

In 2023, Altimmune Inc's operating cash flow was $0 while its capital expenditure stood at $38000.

Comparatively, Altimmune Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$4.32

52-Week High

$23.49

52-Week Low

$3.83

Analyst Target Price

$29.38

Altimmune Inc stock is currently trading at $4.32 per share. It touched a 52-week high of $23.49 and a 52-week low of $23.49. Analysts tracking the stock have a 12-month average target price of $29.38.

Its 50-day moving average was $12.21 and 200-day moving average was $12.6 The short ratio stood at 4.78 indicating a short percent outstanding of 0%.

Around 81.4% of the company’s stock are held by insiders while 9414.2% are held by institutions.